Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus

Abstract

Spanish

French

Objective:

To discuss current and potential treatment options for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA).

Data Sources:

A MEDLINE search (1966–January 2007) was conducted to identify English-language literature on pharmacotherapy of nosocomial pneumonia and the bibliographies of pertinent articles. Programs and abstracts from infectious disease meetings were also searched. Search terms included MRSA, nosocomial pneumonia, pulmonary infections, vancomycin, quinupristin/dalfopristin, linezolid, daptomycin, tigecycline, dalbavancin, oritavancin, and ceftobiprole.

Data Selection and Data Extraction:

All articles were critically evaluated and all pertinent information was included in this review.

Data Synthesis:

Vancomycin has been the drug of choice for MRSA infections for many years. Recent data suggest that linezolid may be superior to vancomycin in the treatment of MRSA nosocomial pneumonia. However, there are limitations to the available data. Therefore, prospective, randomized studies are needed before linezolid is recommended as the preferred first-line therapy. Other approved agents for nosocomial MRSA infections, such as quinupristin/dalfopristin and daptomycin, should not be used in the treatment of MRSA pneumonia, as they were inferior in clinical trials. Tigecycline has excellent activity against MRSA in vitro, but should not be routinely used for the treatment of MRSA pneumonia, as clinical data are lacking. In a Phase III clinical trial, an anti-MRSA cephalosporin, ceftobiprole, is being evaluated for effectiveness against nosocomial pneumonia. Investigational glycopeptides may eventually have a role in the treatment of nosocomial pneumonia, but data are currently lacking.

Conclusions:

Vancomycin is still the drug of choice for treatment of MRSA pneumonia, and linezolid should be used as an alternative agent. Linezolid should carry strong consideration for patients with vancomycin-induced nephrotoxicity or a documented lack of response to vancomycin. Tigecycline and investigational agents with activity against MRSA may be future options for nosocomial pneumonia due to MRSA.

Keywords

linezolid methicillin-resistant Staphylococcus aureus nosocomial pneumonia vancomycin

Get full access to this article

View all access options for this article.

References

Kollef

. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004;32:1396–405.

Richards

Edwards

Culver

Gaynes

. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887–92.

Rello

Ollendorf

Oster

. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115–21.

Warren

Shukla

Olsen

. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312–7.

Kuehnert

Hill

Kupronis

Tokars

Solomon

Jernigan

. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005;11:868–72.

Rello

Torres

Ricart

. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994;150:1545–9.

Pujol

Corbella

Pena

. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998;17:622–8.

Shorr

Combes

Kollef

Chastre

. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006;34:700–6.

Combes

Luyt

Fagon

. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004;170:786–92.

10.

DeRyke

Lodise

Jr.

Rybak

McKinnon

. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005;128:1414–22.

11.

Kollef

Sherman

Ward

Fraser

. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–74.

12.

Soriano

Martinez

Mensa

. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000;30:368–73.

13.

Zahar

Clec'h

Tafflet

. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005;41:1224–31.

14.

Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416.

15.

Fagon

Patrick

Haas

. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161:753–62.

16.

Rubinstein

Cammarata

Oliphant

Wunderink

. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402–12.

17.

Wunderink

Cammarata

Oliphant

Kollef

. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980–92.

18.

Wunderink

Rello

Cammarata

Croos-Dabrera

Kollef

. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789–97.

19.

Kollef

Rello

Cammarata

Croos-Dabrera

Wunderink

. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388–94.

20.

Sabol

Echevarria

Lewis

2nd . Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother 2006;40:1125–33. Epub 30 May 2006. DOI 10345/aph.1G404

21.

Package insert. Vancomycin hydrochloride. Lake Forest, IL: Hospira, August 2004.

22.

Jeffres

Isakow

Doherty

. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care–associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947–55.

23.

Moise

Schentag

. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000;16(suppl 1):S31–4.

24.

Hidayat

Hsu

Quist

Shriner

Wong-Beringer

. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138–44.

25.

Cruciani

Gatti

Lazzarini

. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865–9.

26.

Sakoulas

Moise-Broder

Schentag

Forrest

Moellering

Jr.

Eliopoulos

. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398–402.

27.

Hyatt

McKinnon

Zimmer

Schentag

. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995;28:143–60.

28.

Moise

Forrest

Bhavnani

Birmingham

Schentag

. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57(suppl 2):S4–9.

29.

Moise-Broder

Forrest

Birmingham

Schentag

. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925–42.

30.

Rodvold

Gotfried

Louitit

Porter

. Plasma and intrapulmonary concentrations of oritivancin and vancomycin in normal health adults (abstract 0254). In: Abstracts of thel4th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic, May 1-4, 2004.

31.

Nix

Goodwin

Peloquin

Rotella

Schentag

. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991;35:1947–52.

32.

Downs

Neihart

Dolezal

Hodges

. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989;149:1777–81.

33.

Karam

McKinnon

Neuhauser

Rybak

. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999;19:257–66.

34.

Sorrell

Collignon

. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985;16:235–41.

35.

Batts

Lavin

Eliopoulos

. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy—a status report. Curr Clin Top Infect Dis 2001;21:227–51.

36.

Conte

Jr.

Golden

Kipps

Zurlinden

. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475–80.

37.

Powers

Ross

Lin

Soreth

. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 2004;126:314–5; author reply 5-6.

38.

Bearden

Rodvold

. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000;38:415–26.

39.

Wurtz

Itokazu

Rodvold

. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112–8.

40.

Stein

Schooley

Peloquin

. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005;39:427–32. Epub 8 Feb 2005. DOI 10.1345/aph.1E484

41.

Morales-Molina

Mateu-de Antonio

Marin-Casino

Grau

. Linezolid-associated serotonin syndrome: what we can learn from cases reported so far. J Antimicrob Chemother 2005;56:1176–8.

42.

Lawrence

Adra

Gillman

. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006;42:1578–83.

43.

Taylor

Wilson

Estes

. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006;43:180–7.

44.

Gerson

Kaplan

Bruss

. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723–6.

45.

Weigelt

Kaafarani

Itani

Swanson

. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760–6.

46.

Weigelt

Itani

Stevens

Lau

Dryden

Knirsch

. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260–6.

47.

Birmingham

Rayner

Meagher

Flavin

Batts

Schentag

. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36:159–68.

48.

Lipsky

Itani

Norden

. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin–sulbactam/amoxicillin–clavulanate. Clin Infect Dis 2004;38:17–24.

49.

Nasraway

Shorr

Kuter

O'grady

Cammarata

. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003;37:1609–16.

50.

Kulkarni

Del Priore

. Linezolid induced toxic optic neuropathy. Br J Ophthalmol 2005;89:1664–5.

51.

Lee

Burger

Shah

. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003;37:1389–91.

52.

De Vriese

Coster

Smet

. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006;42:1111–7.

53.

Mullins

Kuznik

Shaya

. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus Clin Ther 2006; 28: 1184–98.

54.

Machado

Arns Cda

Follador

Guerra

. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation–associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Braz J Infect Dis 2005; 9: 191–200.

55.

Shorr

Susla

Kollef

. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004;32:137–43.

56.

Willke

Pinto

. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001;21:263–74.

57.

Sharpe

Shively

Polk

Jr. . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 189: 425–8.

58.

Eliopoulos

. Quinupristin–dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473–81.

59.

Lamb

Figgitt

Faulds

. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999;58:1061–97.

60.

Rubinstein

Prokocimer

Talbot

. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999;44(suppl A):37–46.

61.

Package insert. Cubicin (daptomycin for injection). Lexington, MA: Cubist Pharmaceuticals, September 2003.

62.

Silverman

Mortin

Vanpraagh

Alder

. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149–52.

63.

Sader

Jones

Dowzicky

Fritsche

. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005;52:203–8.

64.

Nathwani

. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005;25:185–92.

65.

Cada

Levien

Baker

. Tigecycline. Hosp Pharm 2005;40:897–907.

66.

Muralidharan

Micalizzi

Speth

Raible

Troy

. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220–9.

67.

Meagher

Passarel

Liolios

. Pharmacokinetic-pharmacodynamic (PK-PD) model for the safety of tigecycline in patients with complicated skin and skin-structure infections (cSSSI) (abstract 525). In: Abstracts of the 43rd annual meeting of the Infectious Diseases Society of America, San Francisco, October 6–9, 2005.

68.

Fritsche

Sader

Stilwell

Dowzicky

Jones

. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005;52:187–93.

69.

Conte

Jr.

Golden

Kelly

Zurlinden

. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523–9.

70.

Study evaluating tigecycline versus imipenem/cilastatin in hospital-acquired pneumonia. National Library of Medicine; 2004-2006. www.clinicaltrials.gov/ct/gui/show/NCT00080496?order=1 (accessed 2006 Sept 25).

71.

Bacilea announces positive phase II results for ceftobiprole, its first-in-class anti-MRSA cephalosporin. Basel, Switzerland: Basilea Pharmaceutica AG, March 2, 2006.

72.

Bacilea's first-in-class antibiotic BAL 5788 (ceftobiprole) moves into hospital-acquired pneumonia phase III clinical trials. Basilea delivers on an additional important clinical milestone. Basel, Switzerland: Basilea Pharmaceutica AG, April 8, 2005.

73.

Abbanat

Macielag

Bush

. Novel antibacterial agents for the treatment of serious gram-positive infections. Expert Opin Investig Drugs 2003;12:379–99.

74.

Andes

Craig

. In vivo pharmacodynamic characteristics of dalbavancin (DAL) in the murine thigh infection model (abstract A-1872). In: Abstracts of the 44th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.

75.

Goldstein

Seltzer

Hamm

Sahm

. Dalbavancin (DAL) phase 3 skin and skin structure (SSSI) studies: pathogens and microbiological efficacy (abstract L-1577). In: Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.

76.

Raad

Darouiche

Vazquez

. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374–80.

77.

Jauregui

Babazadeh

Seltzer

. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407–15.

78.

Leighton

Gottlieb

Dorr

. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004;48:940–5.

79.

Van Bambeke

. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004;4:471–8.

80.

Boylan

Campanale

Iversen

Phillips

Zeckel

Parr

Jr. . Pharmacodynamics of oritavancin (LY333328) in a neutropenicmouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003;47:1700–6.

81.

Pea

Viale

. The antimicrobial therapy puzzle: could pharmacokineticpharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006;42:1764–71.

82.

Blot

. MRSA pneumonia: better outcome through continuous infusion of vancomycin? Crit Care Med 2005;33:2127–8.

83.

Plosker

Figgitt

. Linezolid: a pharmacoeconomic review of its use in serious gram-positive infections. Pharmacoeconomics 2005;23:945–64.

84.

Meka

Gold

. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39:1010–5.

85.

Potoski

Adams

Clarke

. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 2006;43:165–71.